TEST - Catálogo BURRF
   

National Institute of Allergy and Infectious Diseases, NIH : (Registro nro. 289156)

Detalles MARC
000 -CABECERA
campo de control de longitud fija 09530nam a22003855i 4500
001 - NÚMERO DE CONTROL
campo de control 289156
003 - IDENTIFICADOR DEL NÚMERO DE CONTROL
campo de control MX-SnUAN
005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN
campo de control 20160429154659.0
007 - CAMPO FIJO DE DESCRIPCIÓN FÍSICA--INFORMACIÓN GENERAL
campo de control de longitud fija cr nn 008mamaa
008 - DATOS DE LONGITUD FIJA--INFORMACIÓN GENERAL
campo de control de longitud fija 150903s2009 xxu| o |||| 0|eng d
020 ## - NÚMERO INTERNACIONAL ESTÁNDAR DEL LIBRO
Número Internacional Estándar del Libro 9781603272971
-- 9781603272971
024 7# - IDENTIFICADOR DE OTROS ESTÁNDARES
Número estándar o código 10.1007/9781603272971
Fuente del número o código doi
035 ## - NÚMERO DE CONTROL DEL SISTEMA
Número de control de sistema vtls000343211
039 #9 - NIVEL DE CONTROL BIBLIOGRÁFICO Y DETALLES DE CODIFICACIÓN [OBSOLETO]
Nivel de reglas en descripción bibliográfica 201509030903
Nivel de esfuerzo utilizado para asignar no-encabezamientos de materia en puntos de acceso VLOAD
Nivel de esfuerzo utilizado en la asignación de encabezamientos de materia 201405050253
Nivel de esfuerzo utilizado para asignar clasificación VLOAD
-- 201402061150
-- staff
040 ## - FUENTE DE LA CATALOGACIÓN
Centro catalogador/agencia de origen MX-SnUAN
Lengua de catalogación spa
Centro/agencia transcriptor MX-SnUAN
Normas de descripción rda
050 #4 - CLASIFICACIÓN DE LA BIBLIOTECA DEL CONGRESO
Número de clasificación QR180-189.5
100 1# - ENTRADA PRINCIPAL--NOMBRE DE PERSONA
Nombre de persona Georgiev, Vassil St.
Término indicativo de función/relación editor.
9 (RLIN) 44583
245 10 - MENCIÓN DE TÍTULO
Título National Institute of Allergy and Infectious Diseases, NIH :
Resto del título Volume 2;Impact on Global Health /
Mención de responsabilidad, etc. edited by Vassil St. Georgiev.
250 ## - MENCIÓN DE EDICIÓN
Mención de edición 1.
264 #1 - PRODUCCIÓN, PUBLICACIÓN, DISTRIBUCIÓN, FABRICACIÓN Y COPYRIGHT
Producción, publicación, distribución, fabricación y copyright Totowa, NJ :
Nombre del de productor, editor, distribuidor, fabricante Humana Press,
Fecha de producción, publicación, distribución, fabricación o copyright 2009.
300 ## - DESCRIPCIÓN FÍSICA
Otras características físicas recurso en línea.
336 ## - TIPO DE CONTENIDO
Término de tipo de contenido texto
Código de tipo de contenido txt
Fuente rdacontent
337 ## - TIPO DE MEDIO
Nombre/término del tipo de medio computadora
Código del tipo de medio c
Fuente rdamedia
338 ## - TIPO DE SOPORTE
Nombre/término del tipo de soporte recurso en línea
Código del tipo de soporte cr
Fuente rdacarrier
347 ## - CARACTERÍSTICAS DEL ARCHIVO DIGITAL
Tipo de archivo archivo de texto
Formato de codificación PDF
Fuente rda
490 0# - MENCIÓN DE SERIE
Mención de serie Infectious Disease
500 ## - NOTA GENERAL
Nota general Springer eBooks
505 0# - NOTA DE CONTENIDO CON FORMATO
Nota de contenido con formato Microbiology and Infectious Diseases -- NIAID International Research Programs: Global Impact -- Bacterial Diseases -- Emerging and Re-emerging Infectious Diseases -- Fungal Diseases -- Tropical Medicine and Parasitic Diseases -- Virology -- Sexually Transmitted Infections -- Enteric Diseases -- Respiratory Diseases -- Streptococcus pneumoniae (Pneumococcal) Disease -- Severe Acute Respiratory Syndrome -- Influenza -- Tuberculosis -- Viral Hepatitis -- West Nile Virus -- Herpesviruses -- Paramyxoviridae: Nipah Virus and Hendra Virus -- Arthropod-Borne Viral Encephalitis -- Malaria -- Rickettsia: The Typhus Group -- Tick-Borne Bacterial, Rickettsial, Spirochetal, and Protozoal Diseases -- Defense Against Biological Weapons (Biodefense) -- Antimicrobial Resistance and Health Care–Acquired Infections -- Genomic and Postgenomic Research -- Drug Development Research -- Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome -- NIAID: Extramural Basic Research Programs -- NIAID: Programs in HIV Prevention -- NIAID: Programs in HIV/AIDS Therapeutics -- NIAID: Programs in HIV Vaccines -- NIAID: International Involvement in HIV/AIDS Research -- HIV/AIDS Epidemiology -- HIV Therapeutics: Antiretroviral Drugs and Immune-Based Therapies -- Vaccine Development -- Opportunistic Infections -- Immunology Research -- Mammalian Host Defenses: Innate and Adaptive Immunity -- Immune Adjuvants -- Immune Tolerance -- Autoimmune Diseases -- Mucosal Immune System -- The Role of B Cells -- Transplantation -- Asthma and Allergic Diseases.
520 ## - SUMARIO, ETC.
Sumario, etc. I N F E C T I O U S D I S E A S E® Vassil St. Georgiev, Series Editor National Institute of Allergy and Infectious Diseases, NIH Volume 2: Impact on Global Health Vassil St. Georgiev, PhD with Foreword by Antony S. Fauci, MD National Institute of Allergy and Infectious Diseases, National Institutes of Health, DHHS, Bethesda, MD For more than 50 years, the mission of the national Institute of Allergy and Infectious Disease (NIAID)has been to conduct and support basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases with the ultimate goal of improving the health of individuals in the United States and around the world. As part of its mission to foster biomedical research and to reduce the burden of human disease, NIAID is committed to encouraging the accelerated translation of biomedical discoveries into effective clinical care and public throughout the world. In pursuit of this goal and its disease-specific scientific objectives, NIAID seeks to broaden its global impact by increasing scientific opportunities and collaborations involving scientists and institutions outside the United States. The ever increasing efforts of NIAID to combat the worldwide HIV/AIDS, malaria, as well as the increasing numbers of humans infected by highly virulent strains of avian influenza in Asia and elsewhere. NIAID is at the forefront of efforts to address these and other international health challenges by supporting programs in approximately 90 countries and to have dramatically increased spending on international activities in the past decade in a clear strategy to not only devote more resources within the United States to the study of diseases with global health importance, but also to develop the capacity for advanced research within resource-poor nations. Extensive and in-depth, National Institute of Allergy and Infectious Diseases, NIH: Volume 2, Impact on Global Health is a valuable and comprehensive guide providing up-to-date accounts on the state of specific research endeavors in the areas of microbiology and infectious diseases (other than AIDS), HIV/AIDS, allergy, immunology, and transplantation, covering the research portfolios of the NIAID’s extramural divisions of Microbiology and Infectious Diseases, AIDS, and Allergy, Immunology and Transplantation. This volume comprises documents of the United States Government and other research information that is in the public domain. Nevertheless, this volume is not an official U.S. Government publication. Features Includes detailed up-to-date overviews of specific research endeavors in microbiology and infectious diseases (other than HIV/AID), HIV/AIDS, allergy, immunology, and transplantation. Contents Foreword: Anthony S. Fauci, MD. Part I. Microbiology and Infectious Diseases. Primary Research Areas in Microbiology and Infectious Diseases (non-HIV/AIDS). NIAID International Research Programs: Global Impact: Africa, Asia, Partnerships. Bacterial Diseases. Emerging and Re-Emerging Infectious Diseases. Fungal Diseases. Tropical Medicine and Parasitic Diseases. Virology. Sexually-Transmitted Diseases. Enteric Diseases. Respiratory Diaeases. Streptococcus pneumoniae (Pneumococcal) Disease. Severe Acute Respiratory Syndrome (SARS). Influenza. Tuberculosis. Viral Hepatitis. West Nile Virus. Herpesviruses. Paramyxoviridae: Nipah Virus and Hendra Virus. Arthropod-Borne Viral Encephalitis: Flaviviruses, Aphaviruses, Bunyaviruses. Malaria. Rickettsia: The Typhus Group. Tick-Borne Bacterial, Rickettsial, Spirochetal, and Protozoal Diseases: Lyme Disease,Tick-Borne Rickettsial Diseases, Tularemia, Souther Tick-Associated Rash Illness, Babesiosis, Tick-Borne Relapsing Fever. Defense against Biological Weapons (Biodefense): History of Biological Warfare, Anthrax, Variola major Virus (Smallpox), Yersinia pestis (Plague), Brucellosis, Coxiella burnetii-Q fever, Glanders, Melioidosis, Viral Hemorrhagic Fever: Filoviruses, Viral Hemorrhagic Fever: Bunyaviridae, Viral Hemorrhagic Fever: Arenaviruses, Viral Hemorrhagic Fever: Flaviviruses, Protein Toxin Weapons, Arthropod-Borne Viral Fever and Arthropathy, NIAID Research Agenda in Biodefense Antimicrobial Resistance and Healthcare-Acquired Infections. Genomic and Post-Genomic Research. Drug Development Research. Part II. Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome. Introduction: Human Immunodeficiency Virus (HIV). NIAID: Programs in HIV Prevention: Clinical Trials. NIAID: Programs in HIV/AIDS Therapeutics: Drug Discovery, Preclinical Drug Development, Clinical Research, Resources for Researchers, NIAID Funding Initiatives, Clinical Trials, Other NIH-Funded Clinical Trials Networks, Clinical Trials Guidelines. NIAID: Programs in HIV Vaccines. NIAID: International Involvement in HIV/AIDS Research: Clinical Trial Network Studies- ACTG, HVTN, IMPAACT, INSIGHT, MTN, Non-Clinical Trial Network Studies, Centers for AIDS Research (CFARs), Comprehensive International Program of Research on AIDS (CIPRA), International Databases to Evaluate AIDS (IeDEA), Male Circumcision, NIAID Collaborative International Research, U.S. Military HIV Research Program (USMHRP) Trials funded by NIAID, Other HIV/AIDS Vaccine Related Work, International AIDS Vaccine Initiative (IAVI), Partnership for AIDS Vaccine Evaluation (PAVE), Center for HIV/AIDS Vaccine Immunology (CHAVI), Global HIV Vaccine Enterprise (GHVE), President’s Emergency Plan for AIDS Research (PEPFAR). HIV/AIDS Epidemiology. HIV Therapeutics - Antiretroviral Drugs and Immune-Based Therapies: HIV Reverse Transcriptase, HIV Reverse Transcriptase Inhibitors: Nucleoside Analogues, Nucleotide Analogues: Tenofovir DF, Reverse Transcriptase Inhibitors: Non-Nucleoside Analogues, HIV Protease, HIV Protease Inhibitors, Fixed-Dose Combinations, Viral Entry/Fusion Inhibitors, Integrase Inhibitors, Maturation Inhibitors, HAART: Triple Highly Active Antiretroviral Combinations. Vaccine Development: Vaccine Clinical Trials, Vaccine Discovery and Development/Clinical Research, The Failure of the STEP Trial. Opportunistic Infections: Fungal Infections, Viral Infections, Parasitic Infections, Recent NIAID-Supported Clinical Studies in Opportunistic Infections. Part III. Immunoogy Research. Introduction. Mammalian Host defenses:Innate and Adaptivr Immunity. Immune Adjuvants. Immune Tollerance. Autoimmune Diseases. Mucosal Immune System. The Role of B-Cells. Transplantation. Asthma and Allergic Diseases.
590 ## - NOTA LOCAL (RLIN)
Nota local Para consulta fuera de la UANL se requiere clave de acceso remoto.
710 2# - PUNTO DE ACCESO ADICIONAL--NOMBRE DE ENTIDAD CORPORATIVA
Nombre de entidad corporativa o nombre de jurisdicción como elemento de entrada SpringerLink (Servicio en línea)
9 (RLIN) 299170
776 08 - ENTRADA/ENLACE A UN FORMATO FÍSICO ADICIONAL
Información de relación/Frase instructiva de referencia Edición impresa:
Número Internacional Estándar del Libro 9781603272964
856 40 - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS
Identificador Uniforme del Recurso <a href="http://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-60327-297-1">http://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-60327-297-1</a>
Nota pública Conectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 ## - ELEMENTOS DE PUNTO DE ACCESO ADICIONAL (KOHA)
Tipo de ítem Koha Recurso en línea

No hay ítems disponibles.

Universidad Autónoma de Nuevo León
Secretaría de Extensión y Cultura - Dirección de Bibliotecas @
Soportado en Koha